GlassScriptPhysician profile
Amar Srivastava
NPI 1235549031
$3,568.36
in general payments reported to CMS, 2019-2025
7 companies · $969 in 2025
The $969 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2021: $151 · 2022: $2,026 · 2023: $273 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $681 · Food and Beverage: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $681.37 |
| Food and Beverage | $561.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viewray Technologies INC | $1,813.64 | 2022 | |
| Elekta, INC. | $1,114.12 | 2022-2025 | Leksell Gamma Knife Icon, Elekta Unity, Elekta Medical Linear Accelerator |
| Siemens Medical Solutions USA, INC. | $404.09 | 2021-2023 | Aria Radiation Therapy Management Software |
| Novocure INC. | $149.36 | 2019 | |
| Telix Pharmaceuticals | $33.09 | 2025 | Illuccix |
| Sumitomo Pharma America, INC. | $27.99 | 2025 | Orgovyx |
| Myovant Sciences INC. | $26.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Srivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.